5 Reasons Not to Worry About Next Year By Rick

New Post Public Reply Private Reply Replies (1) Message Board
fitzkarz

5 Reasons Not to Worry About Next Year

It's not a perfect world out there for investors, but things may be starting to get better.

I recently went over some of the companies that are expected to post lower quarterly profits next year. Thankfully, they're the exceptions and not the rule. Despite the many economic uncertainties, Wall Street sees most companies building on their 2012 profitability.

Let's go over some publicly traded companies that are expected to stand tall next year by posting year-over-year improvement on the bottom line.

Company

Next Year EPS (estimated)

This Year EPS

My

Watchlist

Amarin ( NASDAQ: AMRN )

($0.73)

($1.48)

Add

Molycorp ( NYSE: MCP )

$0.17

$0.02

Add

Alcatel-Lucent ( NYSE: ALU )

($0.18)

($0.08)

Add

3D Systems ( NYSE: DDD )

$1.57

$1.23

Add

Peregrine Pharmaceuticals ( NASDAQ: PPHM )

($0.29)

($0.31)

Add

Source: Thomson Reuters.

Clearing the table
Let's start at the top with Amarin.

Investors have been rallying behind drugmakers in the battle against the bulge and diet-related risks, and the prospects are bright for Amarin's triglyceride-lowering drug, Vascepa.

Shares of Amarin have come under fire since announcing plans to take on $100 million in debt to finance its own sales force to market Vascepa. The market has historically warmed up to big pharma partners stepping up for this stage of a drug's marketing, partly because it often results in an eventual buyout.

Amarin will still burn through money in 2013, but analysts see the volatile company shaving its deficit roughly in half in the year ahead.

Molycorp is a fallen darling. It was hailed as a growth stock when it went public two years ago, championing the rare earth elements craze. Things haven't been easy these days, and the stock took a hit last week when its CEO surprisingly left the company. It doesn't help that the SEC is investigating the company's earlier financials.

Analysts see Molycorp barely breaking even in 2012, but they do see profitability improving to $0.17 a share in 2013. Yes, this is 90% less than the $1.70 a share that the company rang up in 2011, but it's all about taking baby steps in the right direction.

Alcatel-Lucent shares have rallied more than 50% since bottoming out two months ago. The provider of networking and communications equipment got a new lease on life earlier this year, raising $2.12 billion in new debt financing that will help it push out its current maturities a few year. That should be enough time to give the Paris-based company's home turf of Europe -- and the rest of the world, really -- time to improve to the point of ordering more telecommunications gear again.

3-D printing is a niche that David Gardner's been excited about for some time, and now the rest of the investing world is starting to take notice. 3D Systems has been a big winner along the way, more than tripling in 2012 alone.

The ability to print out physical products -- from smartphone cases to Lego replacement pieces -- is something that will become a reality to more people as the price of these high-tech printers gets cheaper and they become easier to use and program. 3D Systems is leading the way, and the healthy earnings growth and even more robust recent capital appreciation bears that out.

Finally we have Peregrine Pharmaceuticals. The biotech is working on a promising treatment for non-small-cell lung cancer that will pay off big for investors if things pan out. Yes, Peregrine is losing money, but it's been losing less of it with every passing period.

The past few quarters have been encouraging, especially as Peregrine has clocked in with losses that are narrower than what the pros have been targeting. As I recently pointed out , Peregrine bested bottom-line estimates by 23%, 36%, and 33% in its past three quarters, respectively.

Cross those fingers, but know the fundamentals
Investors in these five stocks have a right to be excited. They are all improving their financial situations. They are worthy of the gains that the market rally has bestowed upon them over the past year.

I wouldn't be uncomfortable owning any of these companies. They're doing the right thing, regardless of Mr. Market's mood swings.

The expectations may be high, but these five stocks wouldn't have it any other way.

2013 and beyond
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in our brand-new free report: " The Motley Fool's Top Stock for 2013 ." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.

Your 98.79% Chance at Beating the Market
If you're interested in the best odds in the universe — including more than a 70% chance at DOUBLING the market's return over the long haul — here's some very good news for you... Motley Fool Supernova is re-opening to new members for the first time ever on January 15!

Get this: We arrived at these odds from 10,000 random back-tested portfolios made up of Co-founder David Gardner's personal stock picks between December 2002 and December 2011...

So, what's INSIDE Motley Fool Supernova ?!? Simply enter your email address. And David Gardner will take you on a personal tour. And reveal his up-to-the-minute top picks for 3-D Printing, Entertainment, Social Networking, Personal Wellness, Next-Gen Education, and more!

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 5

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Micro Irrigation Systems: The Future of Sustainable Farming

Updated Category News Views 184

Micro Irrigation Systems: Transforming Global Agriculture The micro irrigation systems market is poised for remarkable growth, expected to expand significantly due to the increasing demand for sustainable agricultural practices. These systems are projected to elevate market valuation from USD 10.9 billion to USD 27.4 billion over the next decade, exhibiting a strong CAGR...

Continue Reading
Empowering Communities: Diaspora Groceries Supplier Summit Launch

Updated Category News Views 276

Empowering Communities: Diaspora Groceries Supplier Summit Launch Diaspora Groceries is thrilled to announce its inaugural Diaspora Diversity Supplier Summit, in partnership with its newly established nonprofit arm, Diaspora Groceries Cares. Taking place over two transformative days, the summit invites food suppliers, farmers, and advocates to gather for insightful...

Continue Reading
EMP Metals Unveils Enhanced Resource Estimate for Lithium Projects

Updated Category News Views 95

EMP Metals Reports Updated Resource Estimate EMP Metals Corp. (CSE: EMPS, OTCQB: EMPPF) is thrilled to share an updated Technical Report detailing the resource estimates for its Viewfield and Mansur lithium brine projects. This comprehensive report showcases a remarkable increase in the total resource, significantly boosting both the indicated and inferred lithium...

Continue Reading
Exploring the Impact of Google Cloud in Enterprise Solutions

Updated Category News Views 264

ISG Evaluates Google Cloud Partner Ecosystem Information Services Group (ISG) (Nasdaq: III), a prominent global technology research and advisory firm, is embarking on an in-depth research study that will gauge the effectiveness of service providers in supporting enterprises using the Google Cloud Platform (GCP) for artificial intelligence (AI) and various other workloads....

Continue Reading
HiRO Joins Forces with CHA University for Future of Health

Updated Category News Views 294

HiRO Collaborates with CHA University Bundang Medical Center Harvest Integrated Research Organization (HiRO), a distinguished global clinical research organization (CRO), has recently entered into a strategic partnership with CHA University Bundang Medical Center (CBMC), a highly respected medical institution in South Korea. This collaboration promises to strengthen the...

Continue Reading